Acro Biomedical Co Stock EBITDA
| ACBM Stock | USD 0 0.00 0.00% |
ACRO Biomedical Co fundamentals help investors to digest information that contributes to ACRO Biomedical's financial success or failures. It also enables traders to predict the movement of ACRO Pink Sheet. The fundamental analysis module provides a way to measure ACRO Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ACRO Biomedical pink sheet.
ACRO |
ACRO Biomedical Co Company EBITDA Analysis
ACRO Biomedical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current ACRO Biomedical EBITDA | (7.69 M) |
Most of ACRO Biomedical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ACRO Biomedical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, ACRO Biomedical Co reported earnings before interest,tax, depreciation and amortization of (7.69 Million). This is 100.88% lower than that of the Healthcare sector and 107.68% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.2% higher than that of the company.
ACRO EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACRO Biomedical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ACRO Biomedical could also be used in its relative valuation, which is a method of valuing ACRO Biomedical by comparing valuation metrics of similar companies.ACRO Biomedical is currently under evaluation in ebitda category among its peers.
ACRO Fundamentals
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 | |||
| Operating Margin | (17.61) % | |||
| Current Valuation | 240.18 M | |||
| Shares Outstanding | 60.04 M | |||
| Shares Owned By Insiders | 49.97 % | |||
| Price To Book | 487.98 X | |||
| Price To Sales | 267.90 X | |||
| Revenue | 1.2 M | |||
| Gross Profit | 259.5 K | |||
| EBITDA | (7.69 M) | |||
| Net Income | 7.7 M | |||
| Cash And Equivalents | 12.11 K | |||
| Total Debt | 59.44 K | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 7.70 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 299.33 K | |||
| Earnings Per Share | (0.20) X | |||
| Beta | 0.92 | |||
| Market Capitalization | 209.55 M | |||
| Total Asset | 761.08 K | |||
| Net Asset | 761.08 K |
About ACRO Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACRO Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACRO Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACRO Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.